Abbott Laboratories logo

Abbott Laboratories (ABT) stock

ABT · Abbott Laboratories · NYSE

Website
Market cap
$178.69B
P/E
38.5
EPS (TTM)
$2.68
Shares out
1.73B
52-week range44% up the range
$81.97$129.84

What is the latest news on ABT stock?

ABT fell 0.75% to $103.18 on Nov 20, 2026. No ABT story in the last two days; the most recent is below.

PRago
Abbott initiates VOYAGER clinical trial for investigational Encantor™ software-guided balloon-expandable TAVI system to treat aortic stenosis

Abbott's Encantor system includes software-guided deployment technology designed to help optimize valve expansion to the patient's unique anatomy, supporting precise implantation and consistent valve performanceEncantor early feasibility study data will be presented at PCR London Valves 2026ABBOTT PARK, Ill., Nov. 19, 2026 /PRNewswire/ -- Abbott (NYSE:ABT), the global healthcare leader, announced today it has initiated the VOYAGER CE clinical trial evaluating the safety and efficacy of its investigational Encantor™ transcatheter aortic valve implantation (TAVI) software-guided balloon-expandable system for treating symptomatic severe aortic stenosis. The first enrollment in the VOYAGER CE st

All ABT news
Price$103.18-11.00 (-9.63%)
2026-08-202026-11-20

Who owns the most ABT stock?

BlackRock, Inc. was the largest reported holder of ABT at the end of Q2 2026, with 152,563,476 shares worth $13.8 billion. Next came Vanguard Capital Management LLC ($10.3 billion) and State Street Corp ($7.3 billion). In all, 2,965 institutions reported $125.5 billion of ABT in their 13F filings.

All ABT fund holders

Are insiders buying or selling ABT?

Insiders are selling. In the last 90 days 3 insiders sold $46.6 million of ABT in trades reported on Form 4. The latest: Mary K Moreland sold $406K, reported on Nov 6, 2026.

ABT insider trades

Financial highlights

Full financials
Revenue, TTM
$48.23B
Revenue growth
+10.0%
Net income, TTM
$4.70B
Net margin
9.7%
Free cash flow, TTM
$6.76B
Cash
$4.05B

For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.

Latest news

25 items

ABT rankings

News · 26 weeks66-33%
2026-05-31: 12026-06-07: 22026-06-14: 22026-06-21: 22026-06-28: 82026-07-05: 02026-07-12: 22026-07-19: 02026-07-26: 22026-08-02: 02026-08-09: 42026-08-16: 32026-08-23: 32026-08-30: 32026-09-06: 12026-09-13: 32026-09-20: 22026-09-27: 82026-10-04: 32026-10-11: 02026-10-18: 62026-10-25: 32026-11-01: 42026-11-08: 12026-11-15: 32026-11-22: 0
2026-05-312026-11-22
Mix4090d
  • Other17(43%)
  • Insider10(25%)
  • Analyst4(10%)
  • SEC Filings4(10%)
  • Earnings3(8%)
  • Dividends2(5%)
Activity · 52 weeks16881 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news

Our reporting on ABT

Abbott Laboratories (ABT) is a Biotechnology: Pharmaceutical Preparations company listed on NYSE. In the last 30 days Quantisnow tracked 12 wire items for ABT, including 7 press releases and news items, 2 analyst ratings and 2 SEC filings. The most recent was published Nov 19, 2026.

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.

ABT FAQ

9 questions
  • What does Abbott Laboratories do?
    Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo...
  • What is ABT revenue?
    Abbott Laboratories (ABT) reported $48.23B of revenue for the twelve months ended Sep 30, 2026. That is up 10.0% from the year before. Revenue for fiscal 2025 was $44.33B.
  • Is ABT profitable?
    Yes. Abbott Laboratories earned $4.70B in net income for the twelve months ended Sep 30, 2026, a net margin of 9.7%.
  • How much cash and debt does ABT have?
    Abbott Laboratories reported $4.05B in cash and cash equivalents and $31.16B of debt on its most recent balance sheet in SEC filings.
  • Where does ABT stock trade?
    Abbott Laboratories (ABT) is listed on NYSE.
  • What sector and industry is ABT in?
    Abbott Laboratories operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • What are analysts saying about ABT?
    Across the last 8 analyst actions on Abbott Laboratories, there were 3 upgrades and 2 downgrades. The most recent action was from Leerink Partners: Outperform with a $124.00 price target on 2026-11-19. Recent price targets range from $92.00 to $145.00.
  • What companies are similar to ABT?
    Notable peers in the same industry include BSX (Boston Scientific Corporation), DHR (Danaher Corporation), BLCO (Bausch + Lomb Corporation), MDT (Medtronic plc.), SYK (Stryker Corporation). Compare ABT side-by-side with any of them on Quantisnow.
  • How can I track ABT on Quantisnow?
    Quantisnow aggregates Abbott Laboratories's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ABT to receive live email and push alerts on every new disclosure.

Is something on this page wrong, or out of date? Request a change